William Blair analyst Andrew Brackmann has reiterated their bullish stance on LH stock, giving a Buy rating on October 17.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andrew Brackmann has given his Buy rating due to a combination of factors that reflect Labcorp Holdings’ strong performance and future potential. The company’s third-quarter results were largely in line with expectations, with revenue meeting consensus and earnings surpassing them slightly. Despite a slight reduction in full-year revenue guidance due to acquisition timing and foreign exchange impacts, the adjusted EPS guidance was raised, indicating confidence in the company’s profitability.
Brackmann’s positive outlook is also supported by Labcorp’s steady organic growth in diagnostics, stable pricing, and a robust M&A pipeline. The company’s ability to maintain healthy utilization trends and its strategic positioning for future earnings growth, particularly with clarity expected for 2026, contribute to the Buy rating. Additionally, the durability of the company’s expanded multiple and its steady dividend further bolster the long-term investment thesis for Labcorp Holdings.
In another report released on October 17, UBS also maintained a Buy rating on the stock with a $325.00 price target.